{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:08:49Z","timestamp":1791043729767,"version":"4.1.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Evidence regarding the relative effectiveness of bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in reducing mortality and major adverse cardiovascular events (MACEs) is limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare all-cause mortality and nonfatal MACEs associated with BMS vs GLP-1RAs for adults with obesity and diabetes and without known cardiovascular disease.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This observational, retrospective cohort study was based on data obtained from the electronic medical records of Clalit Health Services (Clalit), the largest health care organization in Israel. The study included 6070 members aged 24 years or older, who had diabetes and obesity and no prior history of ischemic heart disease, ischemic stroke, or congestive heart failure. Patients who underwent BMS and patients who received GLP-1RAs from January 1, 2008, through December 31, 2021, were matched 1:1 by age, sex, and clinical characteristics. Follow-up ended December 31, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Initiation of BMS or GLP-1RAs.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was all-cause mortality, assessed by multivariate Cox proportional hazards regression models. The secondary outcome was nonfatal MACEs, assessed by multivariate competing risk models.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 3035 matched pairs of patients (total, 6070; mean [SD] age, 51.0 [9.5] years; 3938 women [64.9%]), who were followed up for a median of 6.8 years (IQR, 4.1-9.4 years). Among those with a diabetes duration of 10 years or less (2371 pairs), mortality was lower for those who underwent BMS than for those treated with GLP-1RAs (hazard ratio [HR], 0.38; 95% CI, 0.25-0.58). This association became nonsignificant when weight loss during the follow-up period was also included in the model (HR, 0.79; 95% CI, 0.43-1.48). Among patients with a duration of diabetes longer than 10 years (664 pairs), no survival advantage was demonstrated for BMS over GLP-1RA (HR, 0.65; 95% CI, 0.39-1.08). The risk for nonfatal MACEs did not differ between the treatment groups (HR, 0.74; 95% CI, 0.49-1.10 among patients with a diabetes duration of \u226410 years; HR, 1.21; 95% CI, 0.80-1.85 among patients with a diabetes duration of &amp;gt;10 years).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, BMS was associated with greater reduced mortality compared with first-generation GLP-1RAs among individuals with a diabetes duration of 10 years or less, mediated via greater weight loss. No differences in the risk for mortality were observed between the treatment modalities among individuals with a longer duration of diabetes, nor in the occurrence of nonfatal MACEs among all patients.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.15392","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T15:33:00Z","timestamp":1717774380000},"page":"e2415392","source":"Crossref","is-referenced-by-count":82,"title":["Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality"],"prefix":"10.1001","volume":"7","author":[{"given":"Dror","family":"Dicker","sequence":"first","affiliation":[{"name":"Internal Medicine Department D and Obesity Clinic, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel"},{"name":"School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael Wolff","family":"Sagy","sequence":"additional","affiliation":[{"name":"Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noga","family":"Ramot","sequence":"additional","affiliation":[{"name":"Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez","family":"Battat","sequence":"additional","affiliation":[{"name":"Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Greenland","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Arbel","sequence":"additional","affiliation":[{"name":"Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel"},{"name":"Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Lavie","sequence":"additional","affiliation":[{"name":"Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel"},{"name":"Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2013Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Reges","sequence":"additional","affiliation":[{"name":"Department of Health Systems Management, Ariel University, Ariel, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"zoi240518r1","doi-asserted-by":"publisher","year":"2023","journal-title":"Rev Endocr Metab Disord","DOI":"10.1007\/s11154-023-09797-2"},{"issue":"12","key":"zoi240518r2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","article-title":"Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK.","volume":"6","author":"Bhaskaran","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10287","key":"zoi240518r3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(21)00591-2","article-title":"Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174?772 participants.","volume":"397","author":"Syn","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"zoi240518r4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11695-020-05068-0","article-title":"All-cause mortality of patients with and without diabetes following bariatric surgery: comparison to non-surgical matched patients.","volume":"31","author":"Dicker","year":"2021","journal-title":"Obes Surg"},{"issue":"12","key":"zoi240518r5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224828","article-title":"Long-term outcomes of macrovascular diseases and metabolic indicators of bariatric surgery for severe obesity type 2 diabetes patients with a meta-analysis.","volume":"14","author":"Yan","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"zoi240518r6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2014.16968","article-title":"Association between bariatric surgery and long-term survival.","volume":"313","author":"Arterburn","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"zoi240518r7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2017.20513","article-title":"Association of bariatric surgery using laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality.","volume":"319","author":"Reges","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"zoi240518r8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ndt\/gfaa075","article-title":"Effects of bariatric surgery on kidney diseases, cardiovascular diseases, mortality and severe hypoglycaemia among patients with type 2 diabetes mellitus.","volume":"36","author":"Wong","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"zoi240518r9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S2213-8587(19)30191-3","article-title":"Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study.","volume":"7","author":"Thereaux","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"zoi240518r10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc16-0236","article-title":"Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations.","volume":"39","author":"Rubino","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi240518r11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"24","key":"zoi240518r12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240518r13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41366-023-01254-z","article-title":"Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.","volume":"47","author":"Stenberg","year":"2023","journal-title":"Int J Obes (Lond)"},{"issue":"22","key":"zoi240518r14","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"zoi240518r15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S2213-8587(17)30061-X","article-title":"Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.","volume":"5","author":"Carlsson","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"zoi240518r16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/eurheartj\/ehac071","article-title":"Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.","volume":"43","author":"van Veldhuisen","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"zoi240518r17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"zoi240518r18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.2337\/dc17-0519","article-title":"All-cause and specific-cause mortality risk after Roux-en-Y gastric bypass in patients with and without diabetes.","volume":"40","author":"Lent","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi240518r19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/SLA.0000000000004369","article-title":"How much weight loss is required for cardiovascular benefits? insights from a metabolic surgery matched-cohort study.","volume":"272","author":"Aminian","year":"2020","journal-title":"Ann Surg"},{"issue":"10157","key":"zoi240518r20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"zoi240518r21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"zoi240518r22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"zoi240518r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113517","article-title":"Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists.","volume":"153","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"zoi240518r24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.soard.2021.09.007","article-title":"Metabolic profiles, energy expenditures, and body compositions of the weight regain versus sustained weight loss patients who underwent Roux-en-Y gastric bypass.","volume":"17","author":"Shantavasinkul","year":"2021","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"zoi240518r25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s11695-015-1908-z","article-title":"Weight regain after gastric bypass: influence of gut hormones.","volume":"26","author":"Santo","year":"2016","journal-title":"Obes Surg"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819703\/dicker_2024_oi_240518_1717165158.73671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T15:33:03Z","timestamp":1717774383000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15392","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}